BLUE 181
Alternative Names: BLUE-181Latest Information Update: 28 Dec 2022
At a glance
- Originator Blue Therapeutics
- Class Analgesics; Anxiolytics; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Opioid kappa receptor modulators; Opioid mu receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Anxiety disorders; Irritable bowel syndrome; Pain
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Anxiety-disorders in USA (IV)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in USA (IV)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Pain in USA (IV)